Breaking News
Investing Pro 0
Last Call for Cyber Monday! Save Now on Claim 60% OFF

Nabriva Therapeutics Earnings, Revenue Miss in Q2

Published Aug 05, 2021 08:22PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

 

 
NBRVF
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.

Nabriva Therapeutics announced earnings per share of $-1.37 on revenue of $487K. Analysts polled by Investing.com anticipated EPS of $-0.3467 on revenue of $7.3M.

Nabriva Therapeutics shares are up 28% from the beginning of the year, still down 86.01% from its 52 week high of $8.29 set on August 6, 2020. They are outperforming the S&P 500 which is up 17.92% from the start of the year.

Nabriva Therapeutics follows other major Healthcare sector earnings this month

Nabriva Therapeutics's report follows an earnings beat by J&J on July 21, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.

UnitedHealth had beat expectations on July 15 with second quarter EPS of $4.7 on revenue of $71.32B, compared to forecast for EPS of $4.43 on revenue of $69.51B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Nabriva Therapeutics Earnings, Revenue Miss in Q2
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Vishal Gupta
Vishal Gupta Aug 05, 2021 10:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
These are incorrect numbers, what i see on TD Ameritrade is that NBRV beats analyst forcast by a good margin. August 5, 2021 04:56 PM ET (BZ Newswire) -- Earnings Nabriva Therapeutics (NASDAQ:NBRV) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 17.14 percent. This is a 107.14 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $8.24 million which beat the analyst consensus estimate of $5.99 million by 37.61 percent. This is a 1.59K percent increase over sales of $487.00 thousand the same period last year.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email